The 2026 Genomics Stack: Follow the DNA
Why Understanding the Architecture Matters
This will be a "best ideas only" bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.
There’s a version of this post that is just five separate company write-ups stacked end-to-end. You have seen that version from every sell-side desk covering the space. It gives you a bull case, a bear case, and a price target for each name in isolation and then it stops, leaving you to figure out how they interact. That last part is, inconveniently, where most of the actual investment insight lives. The names are table stakes but the architecture is the alpha.
What I want to do here is something harder and considerably more useful: map the load-bearing dependencies between these companies — the specific, concrete ways in which one company’s success is structurally necessary for, or additive to, another’s. How a dollar of AI-driven drug discovery demand entering the system at the synthesis layer propagates forward through sequencing infrastructure and eventually reaches clinical diagnostics revenue with a lag of 18 to 24 months that creates systematic mispricings if you know where to look. How the competitive skirmish between ILMN and TXG in spatial genomics is being analytically misread by the market in ways that are simultaneously hurting both valuations when the correct interpretation actually strengthens both theses. How BillionToOne’s sensitivity advantage (which the market is treating as a standalone technology story) is structurally downstream of the same platform investments that 10x Genomics and Illumina have been making for the better part of a decade, and how that matters for thinking about the defensibility of BillionToOne’s position over time. How GRAIL’s FDA outcome (whatever it is) does not exist in isolation from the broader liquid biopsy reimbursement landscape and why a GRAIL approval is actually a commercial accelerant for BillionToOne rather than a competitive threat.